2334|723|Public
5|$|For {{the most}} part, Furman kept quiet about his {{exploits}} during the war. He {{served as president}} of the local rotary club and sang baritone in a barbershop quartet. He retired in 1993, and died of <b>metastatic</b> <b>melanoma</b> on October 14, 2008 at Buckingham's Choice retirement community in Adamstown, Maryland at the age of 93.|$|E
5|$|Grey, Yang, Karev, and Stevens are all {{promoted}} to residents, {{in the season}} four premiere, while O'Malley is forced to repeat his internship year, following his failing of the intern exam. Subsequently, Torres and O'Malley divorce one another, due to him having a sexual affair with Stevens, initially concealing it from Torres. Early in the fourth season, cardiothoracic surgeon Erica Hahn becomes Torres' love interest. During the fifth season, Hahn departs from the series, and O'Malley retakes his intern exam, passing, joining his fellow physicians as a resident. Two new characters are introduced, former United States Army trauma surgeon Dr. Owen Hunt, and pediatric surgeon Dr. Arizona Robbins. Hunt becomes a love-interest for Yang, while Robbins becomes a love-interest for Torres. When Stevens is diagnosed with stage four <b>metastatic</b> <b>melanoma,</b> she and Karev get married {{at the conclusion of}} the fifth season. In addition, Meredith and Shepherd marry, with their vows written on a post-it note.|$|E
5|$|Izzie {{supports}} Alex when {{he discovers}} his new girlfriend has psychiatric problems, and convinces {{him to have}} her committed. She is also handed primary responsibility for the clinic, as Bailey cuts back on her responsibilities. Izzie and Alex go on to rekindle their relationship, though Izzie is concerned when she begins hallucinating Denny. She discovers she has <b>metastatic</b> <b>melanoma</b> (Stage IV) which has spread to her liver, skin, and brain, causing the hallucinations. Her survival chances are estimated at only 5%. She is admitted to Seattle Grace as a patient, and Derek Shepherd (Patrick Dempsey) successfully removes a tumor from her brain. Izzie spends her time in the hospital planning Meredith and Derek's wedding, but when her condition worsens and Derek discovers a second brain tumor, they give the ceremony to Izzie and Alex, who marry {{in front of all}} their friends. The procedure to remove the second tumor from Izzie's brain causes her to lose her short-term memory, and although she soon regains it, she flatlines moments later. The fifth season ends with her friends ignoring her DNR order and attempting to resuscitate her, transposed with images of Izzie in an elevator encountering George, who has been in an accident and is also currently flatlining. Though George dies, Izzie is resuscitated and recovers enough to return to work.|$|E
40|$|Abstract. Background: <b>metastatic</b> <b>melanomas</b> are incurable by {{systemic}} treatment {{and it is}} therefore of the highest concern to develop new therapeutic regimens. RAF kinases {{play a key role}} in the RAS-RAF-MAPK signalling pathway which mediates cellular response to growth signals. An inhibitor of the RAS-RAF-MAPK cascade, sorafenib, has shown promising therapeutic results in treatment of several types of metastatic tumours. It can be hypothesized that <b>metastatic</b> <b>melanomas</b> with activating BRAF mutation may respond to RAF kinase-blocking therapy. The objective of the study was to analyze if the activating BRAF V 600 E mutation is present in <b>metastatic</b> <b>melanomas.</b> Materials and Methods: Fine-needle aspirates from 44 <b>metastatic</b> <b>melanomas</b> were studied. The V 600 E mutation in exon 15 of the BRAF gene was selected for genotyping. A Taq-Man MGB bialleli...|$|R
25|$|<b>Metastatic</b> <b>melanomas</b> can be {{detected}} by X-rays, CT scans, MRIs, PET and PET/CTs, ultrasound, LDH testing and photoacoustic detection.|$|R
40|$|International audienceStage III <b>metastatic</b> <b>melanomas</b> require {{adequate}} adjuvant immunotherapy {{to prevent}} relapses. Prognostic factors are awaited {{to optimize the}} clinical management of these patients. The magnitude of metastatic lymph node invasion and the BRAF V 600 activating mutation have clinical significance. Based on a comprehensive immunophenotyping of 252 parameters per patient in paired blood and metastatic lymph nodes performed in 39 <b>metastatic</b> <b>melanomas,</b> we found that blood markers were as contributive as tumor-infiltrated lymphocyte immunotypes, and parameters associated with lymphocyte exhaustion/suppression showed higher clinical significance than those related to activation or lineage. High frequencies of CD 45 RA þ CD 4 þ and CD 3 e CD 56 e tumor-infiltrated lymphocytes appear to be independent prognostic factors of short progression-free survival. High NKG 2 D expression on CD 8 þ tumor-infiltrated lymphocytes, low level of regulatory T-cell tumor-infiltrated lymphocytes, and low PD-L 1 expression on circulating T cells were retained in the multivariate Cox analysis model to predict prolonged overall survival. Prospective {{studies are needed to}} determine whether such immunological markers may guide adjuvant therapies in stage III <b>metastatic</b> <b>melanomas...</b>|$|R
25|$|Radiotherapy {{has a role}} in the palliation of <b>metastatic</b> <b>melanoma.</b>|$|E
25|$|In 2009 Clinical trial {{participation}} {{was considered the}} standard of care for <b>metastatic</b> <b>melanoma.</b>|$|E
25|$|Two {{kinds of}} {{experimental}} treatments {{developed at the}} National Cancer Institute (NCI), {{have been used in}} <b>metastatic</b> <b>melanoma</b> with tentative success.|$|E
40|$|Stage III <b>metastatic</b> <b>melanomas</b> require {{adequate}} adjuvant immunotherapy {{to prevent}} relapses. Prognostic factors are awaited {{to optimize the}} clinical management of these patients. The magnitude of metastatic lymph node invasion and the BRAFV 600 activating mutation have clinical significance. Based on a comprehensive immunophenotyping of 252 parameters per patient in paired blood and metastatic lymph nodes performed in 39 <b>metastatic</b> <b>melanomas,</b> we found that blood markers were as contributive as tumor-infiltrated lymphocyte immunotypes, and parameters associated with lymphocyte exhaustion/suppression showed higher clinical significance than those related to activation or lineage. High frequencies of CD 45 RA+CD 4 + and CD 3 –CD 56 – tumor-infiltrated lymphocytes appear to be independent prognostic factors of short progression-free survival. High NKG 2 D expression on CD 8 +tumor-infiltrated lymphocytes, low level of regulatory T-cell tumor-infiltrated lymphocytes, and low PD-L 1 expression on circulating T cells were retained in the multivariate Cox analysis model to predict prolonged overall survival. Prospective {{studies are needed to}} determine whether such immunological markers may guide adjuvant therapies in stage III <b>metastatic</b> <b>melanomas...</b>|$|R
40|$|Melanocytic {{neoplasia}} {{is characterized}} by the aberrant overproduction of multiple cytokines in vitro. However, it is largely unknown how cytokine expression relates to melanoma progression in vivo. Transforming growth factor beta (TGF-beta) is a multifunctional cytokine commonly produced by cultured melanoma cells. The in situ expression of all three TGF-beta isoforms (TGF-beta 1, - 2, and - 3) was determined immunohistochemically in melanocytes and in 51 melanocytic lesions using isoform-specific antibodies. Significant linear trends of expression were observed from melanocytes through nevi and primary and <b>metastatic</b> <b>melanomas</b> for all three isoforms. TGF-beta 1 was expressed by some melanocytes and almost uniformly by nevi and melanomas. TGF-beta 2 and - 3 were not expressed in normal melanocytes but were expressed in nevi and early and advanced primary (radial and vertical growth phase) and <b>metastatic</b> <b>melanomas</b> in a tumor-progression-related manner. TGF-beta 2 was heterogeneously expressed in advanced primary and <b>metastatic</b> <b>melanomas,</b> whereas TGF-beta 3 was uniformly and highly expressed in these lesions. Thus, expression of TGF-beta isoforms in melanocytes and melanocytic lesions is heterogeneous and related to tumor progression, and expression of TGF-beta 2 and TGF-beta 3 commences at critical junctures during progression of nevi to primary melanomas...|$|R
30|$|We have {{demonstrated}} that 18 [*]F-FDG-PET imaging reflects vemurafenib and GDC- 0973 action across {{a wide range of}} <b>metastatic</b> <b>melanomas.</b> A delayed post-treatment increase in tumor FDG uptake should be considered carefully as it may well be an indication of acquired drug resistance.|$|R
25|$|In August {{scientists}} successfully treated <b>metastatic</b> <b>melanoma</b> in {{two patients}} using killer T cells genetically retargeted {{to attack the}} cancer cells.|$|E
25|$|In January 2014, the FDA {{approved}} {{the combination of}} dabrafenib and trametinib {{for the treatment of}} patients with BRAF V600E/K-mutant <b>metastatic</b> <b>melanoma.</b>|$|E
25|$|Treatments for <b>metastatic</b> <b>melanoma</b> include {{biologic}} immunotherapy agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor trametinib.|$|E
40|$|Recent {{investigations}} have highlighted the controversial role of Wnt/β-catenin pathway activation in human cutaneous melanoma. Survivin {{has been proposed}} as a valid prognostic marker for invasive and <b>metastatic</b> <b>melanomas</b> and lymph node melanoma metastasis in human cutaneous melanoma and is a promising therapeutic target...|$|R
40|$|High {{levels of}} cytosolic {{cathepsin}} D expression {{have been associated}} with poor prognosis in breast cancer node-negative patients. In this work, we provide evidence that three cell lines established from human metastatic melanomas-IIB-MEL-J, IIB-MEL-LES, and lIB-MEL-IAN-express high levels of procathepsin D mRNA. IIB-MEL-J cells secreted into the conditioned media about 30 % of the newly synthesized protein, which was active at acidic pH. Melanoma tumors arising in nude mice after injection of the three different cell lines expressed high levels of procathepsin D mRNA, Moreover, 13 human <b>metastatic</b> <b>melanomas</b> expressed variable levels of procathepsin D mRNA. To study the possible association between cathepsin D expression and melanoma development, samples corresponding to 10 primary tumors, 11 <b>metastatic</b> <b>melanomas,</b> 10 dysplastic nevi, 27 nevocellular nevi, and normal melanocytes were studied by immunohistochemistry for cathepsin D-specific staining. We found that cathepsin D was expressed in all of the dysplastic nevi and primary and <b>metastatic</b> <b>melanomas</b> tested but in only 18 % of nevocellular nevi (five of 27), whereas normal melanocytes showed no cathepsin D expression. The over- all data indicate that cathepsin D is expressed at a high level by melanoma cells, and because of its expression in preneoplastic lesions, it may be associated with melanoma development...|$|R
40|$|Melanoma antigen {{recognized}} by T cells 1 (MART- 1) and tyrosinase-related protein- 2 (TRP- 2) are two useful markers for immunohistochemical detection of melanocytic tumors. However, these markers may be passively acquired (phagocytosed) rather than actively synthesized. Reverse transcriptase in situ {{polymerase chain reaction}} (RT in situ PCR) can amplify even small amounts of specific mRNA in cells and therefore confirm the cellular source of a marker. We developed a one-step RT in situ PCR procedure in which Thermus thermophilus DNA polymerase synthesizes and amplifies cDNA from mRNA in a single reaction mixture. To examine its practicability and feasibility with formalin-fixed, paraffin-embedded (FFPE) tissue, we compared the results of one-step RT in situ PCR with those of immunohistochemistry (IHC). MART- 1 mRNA was identified in the cytoplasm of lesional cells from 23 / 26 primary melanomas (92 %), 9 / 9 <b>metastatic</b> <b>melanomas</b> (100 %) and 5 / 6 nevi (83 %). MART- 1 epitope was detected by IHC in 23 / 24 primary melanomas (96 %), 9 / 9 <b>metastatic</b> <b>melanomas</b> (100 %) and 5 / 6 nevi (83 %). TRP- 2 mRNA was identified in the cytoplasm of lesional cells from 17 / 26 primary melanomas (65 %), 6 / 9 <b>metastatic</b> <b>melanomas</b> (67 %) and 4 / 6 nevi (67 %). TRP- 2 epitope was detected by IHC in 20 / 24 primary melanomas (83 %), 9 / 9 <b>metastatic</b> <b>melanomas</b> (100 %) and 4 / 6 nevi (67 %). Both techniques detected MART- 1 and TRP- 2 in FFPE melanoma cell lines. Neither marker was detected in squamous cell carcinomas or basal cell carcinomas by RT in situ PCR or IHC. We conclude that the RT in situ PCR technique can be successfully applied to FFPE tissue to determine the cellular sources of gene expression observed by conventional PCR approaches...|$|R
25|$|Various {{chemotherapy}} agents, including temozolomide, dacarbazine (also termed DTIC), immunotherapy (with interleukin-2 (IL-2) or interferon (IFN)), as well {{as local}} perfusion, are used by different centers. The overall success in <b>metastatic</b> <b>melanoma</b> is quite limited.|$|E
25|$|IL-2 (Proleukin) was {{the first}} new therapy {{approved}} (1990 Europe, 1992 USA) {{for the treatment of}} <b>metastatic</b> <b>melanoma</b> in 20 years. Studies have demonstrated that IL-2 offers the possibility of a complete and long-lasting remission in this disease, although only in a small percentage of patients. Intralesional IL-2 for in-transit metastases has a high complete response rate ranging from 40 to 100%.|$|E
25|$|Thy1 {{expression}} varies between species. Amongst {{the cells}} reported to generally express Thy-1 are thymocytes (precursor of T {{cells in the}} thymus) & CD34(+) prothymocytes; neurons, mesenchymal stem cells, hematopoietic stem cells, NK cells, murine T-cells, endothelium (mainly in high endothelial venules or HEVs where diapedesis takes place), renal glomerular mesangial cells, circulating <b>metastatic</b> <b>melanoma</b> cells, follicular dendritic cells (FDC), a fraction of fibroblasts and myofibroblasts.|$|E
40|$|Purpose: To {{assess the}} safety and {{efficacy}} of dendritic cell vaccination in <b>metastatic</b> uveal <b>melanoma.</b> Design: Interventional case series. Methods: We analyzed 14 patients with <b>metastatic</b> uveal <b>melanoma</b> treated with dendritic cell vaccination. Patients with <b>metastatic</b> uveal <b>melanoma</b> received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp 100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival. Results: Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29 %) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19. 2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed. Conclusions: Dendritic cell vaccination is feasible and safe in <b>metastatic</b> uveal <b>melanoma.</b> Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination {{may be associated with}} longer than average overall survival in patients with <b>metastatic</b> uveal <b>melanoma...</b>|$|R
40|$|PurposeTo {{assess the}} safety and {{efficacy}} of dendritic cell vaccination in <b>metastatic</b> uveal <b>melanoma.</b> DesignInterventional case series. MethodsWe analyzed 14 patients with <b>metastatic</b> uveal <b>melanoma</b> treated with dendritic cell vaccination. Patients with <b>metastatic</b> uveal <b>melanoma</b> received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp 100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival. ResultsTumor-specific immune responses were induced with dendritic cell vaccination in 4 (29 %) of  14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19. 2  months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed. ConclusionsDendritic cell vaccination is feasible and safe in <b>metastatic</b> uveal <b>melanoma.</b> Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination {{may be associated with}} longer than average overall survival in patients with <b>metastatic</b> uveal <b>melanoma...</b>|$|R
50|$|The average {{survival}} time after diagnosis of liver metastases {{depends on the}} extent of systemic spread. The disease-free interval, the performance status, the liver substitution by metastases and the serum level of lactic dehydrogenase are the most important prognostic factors for <b>metastatic</b> uveal <b>melanoma.</b> There is currently no cure for <b>metastatic</b> uveal <b>melanoma.</b>|$|R
25|$|In some {{countries}} oncolytic virotherapy methods are studied {{and used to}} treat melanoma. Oncolytic virotherapy is a promising branch of virotherapy, where oncolytic viruses are used to treat diseases; viruses can increase metabolism, reduce anti-tumor immunity and disorganize vasculature. Talimogene laherparepvec (T-VEC) (which is a herpes simplex virus type 1–derived oncolytic immunotherapy), was shown to be useful against <b>metastatic</b> <b>melanoma</b> in 2015 with an increased survival of 4.4 months.|$|E
25|$|Radiation {{therapy is}} often used after {{surgical}} resection for patients with locally or regionally advanced melanoma or for patients with unresectable distant metastases. Kilovoltage x-ray beams are often used for these treatments and have {{the property of the}} maximum radiation dose occurring close to the skin surface. It may reduce the rate of local recurrence but does not prolong survival. Radioimmunotherapy of <b>metastatic</b> <b>melanoma</b> is currently under investigation.|$|E
25|$|Some {{types of}} cancer are notably radioresistant, that is, much higher doses are {{required}} to produce a radical cure than may be safe in clinical practice. Renal cell cancer and melanoma are {{generally considered to be}} radioresistant but radiation therapy is still a palliative option for many patients with <b>metastatic</b> <b>melanoma.</b> Combining radiation therapy with immunotherapy is an active area of investigation and has shown some promise for melanoma and other cancers.|$|E
40|$|Lymph-node aspirates {{performed}} {{over ten}} years numbering 1, 555 showed 8. 2 percent of metastatic tumors. Of these, only six percent were <b>metastatic</b> <b>melanomas.</b> Clinical diagnosis was made in three cases. Melanin in the cells made the diagnosis easy. But {{even in the absence}} of the pigment as in two amelanotic melanomas, the cytologic features were characteristic...|$|R
40|$|Fatty acid-binding protein- 7 (FABP 7) {{has been}} shown to be {{expressed}} in cutaneous melanoma; however, its role in tumor progression is unclear. Expression of FABP 7 was assessed during melanoma progression through assessment of various clinicopathology stages of primary tumor progression and metastasis. FABP 7 mRNA was highly expressed in 60 of 87 (69 %) primary melanomas, compared with significant (P< 0. 0001) reduction in 13 of 68 (19 %) <b>metastatic</b> <b>melanomas.</b> Analysis of 37 paired primary and <b>metastatic</b> <b>melanomas</b> by immunohistochemistry with anti-FABP 7 Ab showed 73 and 27 % positivity, respectively (P< 0. 001). FABP 7 detection of metastatic tissues was inversely correlated with relapse-free (P< 0. 0001) and overall (P< 0. 0001) survival. To examine FABP 7 expression loss in advanced melanomas, loss of heterozygosity (LOH) was assessed using microsatellite markers encompassing the FABP 7 gene. LOH was identified in 10 of 20 (50 %) <b>metastatic</b> <b>melanomas</b> at 6 q 22. 31, compared with 0 of 14 primary melanomas (P= 0. 0017). FABP 7 as a surrogate biomarker for circulating tumor cells (CTCs) in the blood was assessed by quantitative real-time (qRT) –PCR from melanoma patients’ blood (n= 134). Assessment of patients’ blood showed that FABP 7 (+) CTC decreased with disease progression. FABP 7 may function as a tumor progression gene and can be used as a potential diagnostic biomarker of early-stage melanoma systemic spreading in blood...|$|R
40|$|Thesis (M. A.) [...] Boston University PLEASE NOTE: Boston University Libraries did {{not receive}} an Authorization To Manage form for this thesis or dissertation. It is {{therefore}} not openly accessible, {{though it may be}} available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu. edu. Thank you. The prevalence of skin cancer has been continuously increasing in the American population over the last 3 decades. Melanoma, the most serious and dangerous form, causes the most skin cancer related deaths. If melanoma is found early enough, it can be treated and cured. Current therapy for melanoma is based on the stage of the disease. It is crucial to identify and treat the melanoma before metastasis occurs as the risk of death greatly increases once the disease becomes widespread. The processes of angiogenesis and lymphangiogenesis as well as changes in the extracellular environment all play significant roles in the expansion of a primary melanoma and ultimately metastasis. Neuropilins, specifically Neuropilin- 2 (NRP 2), {{have been found to be}} associated with both angiogenesis and lymphangiogenesis and thus metastasis. Since it is critical to identify and treat melanoma before it advances to metastasis, the relationship between NRP 2 and tumor progression may prove to be extremely valuable as a prognostic marker for primary melanoma tumors. In addition, it may serve to identify subsets of early stage tumors that would benefit from adjuvant therapy. This study aimed to demonstrate if there is a relationship between the level of expression of NRP 2 in primary melanocytic lesions and the prognosis of melanoma, and determine the potential utility of NRP 2 as a biomarker for melanoma. To do so, the levels of expression of NRP 2 were analyzed in formalin-fixed, paraffin-embedded, tissue samples of nevi, primary <b>melanomas,</b> and <b>metastatic</b> <b>melanomas.</b> Sample RNA was extracted and converted to eDNA. Quantitative RT-PCR was then used to amplify eDNA and appropriate normalizations were performed. Luciferase RNA was added at the start of processing as an exogenous control and was used to correct for procedural variation between samples. Furthermore, Actin, beta (ACTB) and Melan-A were used as reference genes to correct for differences in tissue and lesion size respectively. To analyze the data, standard curves were developed for NRP 2, ACTB, and Melan-A to calculate the copy numbers for each gene in each sample. When normalized by both ACTB and Melan-A, the differences in the level of expression of NRP 2 between nevi and primary melanomas (p= 0. 94422), nevi and <b>metastatic</b> <b>melanomas</b> (p= 0. 29538), and primary <b>melanomas</b> and <b>metastatic</b> <b>melanomas</b> (p= 0. 32827) all failed to show statistical significance. In addition when normalized by only ACTB, there is no statistical significant difference in the level of expression of NRP 2 between nevi and primary melanomas (p= 0. 21001), or primary and <b>metastatic</b> <b>melanomas</b> (p= 0. 30874). However, there is a difference between nevi and <b>metastatic</b> <b>melanomas</b> (p= 0. 00472) that is statistically significant when just normalized by ACTB. Furthermore, when just normalized by Melan-A, there is no significant difference in the level of expression of NRP 2 between nevi and primary melanomas (p= 0. 3152) or primary <b>melanomas</b> and <b>metastatic</b> <b>melanomas</b> (p= 0. 14179). However, there is a statistically significant difference in the level of expression of NRP 2 between nevi and <b>metastatic</b> <b>melanomas</b> (p= 0. 01736). The fact that there is a statistically significant difference (p less than 0. 05) in the level of expression of NRP 2 between nevi and primary melanomas demonstrates its potential ability to be used as a biomarker. However, the inability to establish statistical significance between sample groups may be due to the small sample size. Further studies with an increased sample size may better show the relationship between the levels of NRP 2 and the stage of melanoma. Still, NRP 2 shows promise as both a diagnostic and prognostic biomarker for melanoma...|$|R
25|$|When {{there is}} distant metastasis, the cancer is {{generally}} considered incurable. The five-year survival rate is less than 10%. The median survival is 6–12 months. Treatment is palliative, focusing on life extension and quality of life. In some cases, patients may live many {{months or even years}} with <b>metastatic</b> <b>melanoma</b> (depending on the aggressiveness of the treatment). Metastases to skin and lungs have a better prognosis. Metastases to brain, bone and liver are associated with a worse prognosis. Survival is better with metastasis in which the location of the primary tumor is unknown.|$|E
25|$|Pharmacotherapy {{research}} for unresectable or metastatic malignant melanoma offers new treatment possibilities. In {{addition to the}} advances with recently approved agents, ongoing research into combination therapy, such as dabrafenib and trametinib, may reveal a more effective and better-tolerated option for patients with <b>metastatic</b> <b>melanoma.</b> One important pathway in melanin synthesis involves the transcription factor MITF. The MITF gene is highly conserved and is found in people, mice, birds, and even fish. MITF production is regulated via a fairly straightforward pathway. UV radiation causes increased expression of transcription factor p53 in keratinocytes, and p53 causes these cells to produce melanocyte-stimulating hormone (MSH), which binds to melanocortin 1 receptors (MC1R) on melanocytes. Ligand-binding at MC1R receptors activates adenylate cyclases, which produce cAMP, which activates CREB, which promote MITF expression. The targets of MITF include p16 (a CDK inhibitor) and Bcl2, a gene essential to melanocyte survival. It {{is often difficult to}} design drugs that interfere with transcription factors, but perhaps new drugs will be discovered that can impede some reaction in the pathway upstream of MITF.|$|E
500|$|Heigl {{garnered}} {{critical acclaim}} for her performance as Izzie and received numerous awards and nominations for her role, winning the [...] "Outstanding Supporting Actress In A Drama Series" [...] at the 2007 Emmy Awards. She {{was critical of}} the character's development during the show's fourth season, particularly her romance with George. She declined to put herself forward for the 2008 Emmy Awards, citing insufficient material in the role. After speculation that Izzie would be killed off in the fifth season, the character was diagnosed with Stage 4 <b>metastatic</b> <b>melanoma.</b> She married Alex in the series' one-hundredth episode, and afterwards, her tumor was successfully removed. Izzie made her final appearance in the sixth season, leaving Seattle after Alex refused to resume their marriage. Heigl requested {{to be released from}} her contract 18months early, in order {{to spend more time with}} her family. In January 2012, Heigl reported that she would like to return to Grey's Anatomy to give closure to her character, however, Rhimes confirmed that there were no plans to have the character return at that time and has since stated that she has no plans to ever re-approach Izzie's storyline again.|$|E
40|$|Objective: Grb 2 -associated binder 2 (Gab 2), {{a member}} of the family of Gab {{scaffolding}} adaptors, transmits and amplifies the signals from receptor tyrosine kinases. A recent study demonstrated that Gab 2 was over-expressed in breast cancers and <b>metastatic</b> <b>melanomas,</b> and Gab 2 was an oncogenic protein. However, the roles of Gab 2 in lung cancers are largely unknown...|$|R
40|$|Identification of oncogenic BRAF {{mutations}} in primary and <b>metastatic</b> <b>melanomas</b> supports a linear model of clonal evolution in cancer. Some mutational studies, however, {{have failed to}} identify BRAF {{mutations in}} metastatic tumors from patients with BRAFmutant primary melanomas. Using a combination of methods, Riveiro-Falkenbach et al. (2015) assert that technical issues, and not clonal heterogeneity, may explain prior discordant mutational results...|$|R
40|$|Overexpression of the p 53 {{gene product}} has been {{observed}} in {{a high percentage of}} malignant melanomas. To evaluate the role of this protein in the development of melanoma, we examined p 53 expression in benign, premalignant, and malignant melanocytic lesions. Using the antibodies DO- 7 and 1801, which recognize both wild-type and most mutant forms of the p 53 protein, we analyzed by immunohistochemical staining 26 benign nevi, 34 dysplastic nevi from patients at low risk for the development of melanoma, 22 dysplastic nevi from patients at high risk for the develop ment of melanoma, 61 primary melanomas (including 15 that arose from dysplastic nevi), and 10 <b>metastatic</b> <b>melanomas.</b> Expression of the p 53 protein was not observed in any of the benign or dysplastic nevi. Of the primary melanomas only 3 (5 %) demonstrated nuclear staining, whereas 70 % of the <b>metastatic</b> <b>melanomas</b> showed a positive reaction for p 53. These data suggest that Overexpression of the p 53 gene product is a lat...|$|R
